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Abstract
Background: Polypharmacy and inappropriate drug use is associated with negative health outcomes among older
people. Various interventions for improving drug treatment have been evaluated, but the majority of studies are limited
by the use of surrogate outcomes or suboptimal design. Thus, the potential for clinically significant improvements from
different interventions is still unclear. The main objective of this study is therefore to evaluate the effect upon
patient-relevant endpoints of a cooperation between geriatricians and general practitioners on complex drug
regimens in home-dwelling elderly people.
Methods: This is a cluster randomised, single-blind, controlled trial where general practitioners are invited to
participate with patients from their lists. The patients must be 70 years or older, use at least seven different
medications and have their medications administered by the home nursing service. We plan to recruit 200
patients, with randomisation at physician level. The intervention consists of three main parts: (1) clinical geriatric
assessment of the patient, combined with a thorough review of their medications; (2) a meeting between the geriatrician
and general practitioner, where the two physicians combine their competence and knowledge and discuss the drug list
systematically; (3) clinical follow-up, depending on the medication changes that have been done. The study period is
24 weeks, and the patients are assessed at baseline, 16 and 24 weeks. The primary outcome measure is health-related
quality of life according to the 15D instrument. Secondary outcome measures include physical and cognitive functioning,
medication appropriateness, falls, carer burden, use of health services (hospital or nursing home admissions, use of home
nursing services) and mortality.
Discussion: Our choice of patient-relevant outcome measures will hopefully provide new knowledge on the potential
for clinical improvements after performing comprehensive medication reviews in home-dwelling elderly people receiving
polypharmacy.
Trial registration: ClinicalTrials.gov, NCT02379455. Registered on 27 February 2015.
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Background
Polypharmacy
The drug consumption among older people has increased
in the last decades [1] and polypharmacy is frequent [2]. It
has been shown that 20% of Norwegians aged 70 plus are
prescribed more than ten different drugs annually [3]. In a
study of drug consumption among elderly (65 plus) users
of home services in eight European countries, 51% used
more than six and 22% used more than nine different
drugs during a week [4].
A complex clinical situation involving multimorbidity
may justify a high number of drugs, and a properly titrated
polypharmacy can be beneficial for the individual patient.
However, most therapeutic guidelines are based upon re-
search carried out in patients with a limited number of co-
morbid conditions. Accordingly, such guidelines may be of
limited value in frail and multimorbid elderly patients
[5, 6]. The more drugs an individual patient consumes, the
more demanding is the trade-off between benefits and
harms, and the more tightly should the clinical condition
be monitored. Polypharmacy increases the risk of adverse
drug reactions (ADRs), interactions and other drug-related
problems (DRPs), and the risk increases almost linearly
with the number of drugs used [7–9]. Several studies
among older people indicate that inappropriate drug use is
a major reason for poor health and impaired function
[10–12], preventable hospital admissions [13–15], and
even deaths [16]. A recent Norwegian study reported
that of home-dwelling elderly (75 plus) emergency-
admitted to hospital, almost 40% were prescribed at least
one potentially inappropriate medication (PIM) [17]. DRPs
are often caused by overmedication, choice of inappropri-
ate drugs, or inadequate monitoring and follow-up [12].
Underuse of potentially beneficial drugs is probably also a
significant problem in the elderly [18, 19].
Improving prescribing quality
Optimisation of pharmacotherapy should be based on a
comprehensive assessment of all relevant medical condi-
tions as well as the patient's functional ability, resources
and preferences. However, health services are often orga-
nised in a way that makes it difficult to attain a suffi-
ciently good overview of the clinical situation to make
good medication reviews in frail and multimorbid pa-
tients. Specialists in hospitals mainly see the patient dur-
ing acute exacerbations of their chronic diseases, and
will naturally focus upon drugs relevant for the acute
illness – especially drugs relevant for the organ system
in which they have specialised. On the other side, gen-
eral practitioners (GPs) are responsible for the long-term
follow-up and repeat prescriptions. Because most GPs
attain limited experience in handling complex health
states, they may be reluctant to change medications
initiated by hospital specialists [20]. Geriatricians are
trained in the management of complex health conditions
and polypharmacy and have firm knowledge about age-
related changes in physiology and pharmacology [21],
but typically see patients over a short period of time, ei-
ther in an acute geriatric ward or in the geriatric out-
patient department. Thus, the geriatrician often has
limited information about the patient’s medical history,
and has a limited possibility to follow the patient over
time, elements that are typical strengths in the follow-up
made by the GP. Geriatricians and GPs therefore have
complementary strengths for managing complex drug
regimens in frail elderly patients, and a closer cooper-
ation between these two specialities could be beneficial.
A majority of interventions for improving drug treat-
ment among older people are evaluated by the use of
surrogate outcomes such as frequency of DRPs [22],
number of prescribed drugs [23], or prevalence of PIMs
[24]. Many studies also suffer from suboptimal design,
such as observational studies and interventional studies
without a control group [25] or without randomisation
[26]. A recent Cochrane review [27] concluded that in-
terventions to improve drug therapy appear beneficial in
terms of reducing inappropriate prescribing, but the
clinical benefits of such reductions are unclear. Interven-
tional studies of measures to facilitate better prescrip-
tions, using a scientifically sound design and at the same
time utilising patient-relevant outcomes as well as out-
comes capturing the effect upon the families and the
health care services, are so far very rare.
Study objectives
The aim of this study is to evaluate the effect of drug opti-
misation interventions resulting from a cooperation be-
tween geriatricians and GPs on clinically relevant outcome
measures in home-dwelling elderly people using complex
drug regimens.
Methods/design
Study design
This is a cluster randomised, single-blind, controlled
trial with 24 weeks follow-up. GPs are recruited to par-
ticipate in the study with patients from their lists. In
order to avoid “contamination” between intervention
and control patients, cluster randomisation on physician
level instead of individual randomisation on patient level
is performed. The outcomes are assessed at baseline and
after 16 and 24 weeks. Patient flow is illustrated in Fig. 1.
See Additional file 1 for the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
checklist and Additional file 2 for the SPIRIT figure.
Recruitment of GPs
GPs from the counties of Akershus and Oslo, Norway,
are invited to participate in the study. All GPs in these
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areas are eligible for participation. The GPs receive written
invitations, followed by a phone call to clarify if they are
interested. When possible, information about the study is
also given at GP meetings within each municipality.
Study population
We assume that the comprehensive clinical evaluation
and medication review that we will test is most relevant
for the oldest and most frail patients, with relatively pro-
nounced polypharmacy. We have therefore chosen the
following inclusion and exclusion criteria:
Patient inclusion criteria
– Listed with one of the participating GPs
– Home-dwelling
– Medications administered by the home nursing
service
– Age 70 years or more
– Use of at least seven different systemic medications
taken regularly (preparations for inhalation, vitamin
supplements and laxatives are included, but not
topical drugs like eye drops and ointments)
– Signed informed consent given by the patient or his/
her closest proxy
Patient exclusion criteria
– Expected to become permanently institutionalised
within 6 months
– Life expectancy judged to be 6 months or less
– Moderate/severe dementia (i.e., Clinical Dementia
Rating Scale (CDR) score > 1) and contact with the
closest proxy less than once every other week
– Not speaking or understanding Norwegian
– The GP does not want the particular patient to
participate (in case of important reasons not covered
by the other exclusion criteria)
Screening and inclusion
The majority of home-dwelling patients with medica-
tions administered by the home nursing service have
Fig. 1 CONSORT diagram
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their medications prepared by multi-dose packaging sys-
tems delivered by a pharmacy. Medication lists from the
pharmacy are screened by the home nursing service or
by GP office staff to identify patients fulfilling the inclu-
sion criteria. The GPs then consider the eligibility of
their patients based on the defined exclusion criteria.
Patients eligible for participation are contacted by the
home nursing service or the GP’s office, explaining the
study and asking whether the researchers may contact
them. If this is accepted, the patients receive a home
visit from a research assistant who gives complementary
oral and written information. Informed written consent
is obtained from all participants or from their closest
relative in cases where the patient is unable to give a
valid consent due to reduced cognitive functioning.
Randomisation and blinding
In order to avoid large variation in cluster sizes, each GP
can participate with a maximum of five patients. To
assure as equal group sizes as possible, the GPs are
stratified based on the number of contributing patients;
1–2 patients versus 3–5. Randomisation is computer-
generated and carried out in blocks of unknown and
variable size. The allocation sequence is prepared by a
statistician not involved in recruitment, and is made
available to the researchers in sealed, opaque envelopes.
In order to minimise the risk of selection bias, random-
isation takes place after inclusion of all patients within
each cluster. The GPs are included sequentially accord-
ing to the capacity in the project. The research assistant,
who provides all the assessments, is blinded with respect
to allocation. Given the nature of the intervention, it is
not feasible to blind the patients, their relatives or the
GPs. The effects of the intervention will be analysed
blindly, i.e. with the two randomised groups denominated
“A” and “B” but without knowledge regarding which
group is the control and which the intervention group.
Intervention
Our intervention consists of three main parts: clinical
geriatric assessment of the patient combined with a thor-
ough review of their medications; a targeted meeting be-
tween the geriatrician and the GP; and clinical follow-up.
Geriatric assessment and medication review
The patients receive a home visit by a physician trained
in geriatric medicine (RR). In advance, the geriatrician
obtains necessary information on the patient’s medical
history and actual medication from hospital records, the
GP’s electronic patient record, the home nursing service
and other relevant sources. The geriatrician carries out a
medical history from the patient (if necessary supple-
mented by a close relative) and a physical examination,
both with focus on conditions most relevant for the
patient’s total medication use. Relevant blood analyses
and other supplementary tests are ordered if not already
available (ECG, haematological tests, electrolytes, renal
function, natriuretic peptides, thyroid function, nutri-
tional indicators, serum concentration of relevant drugs,
pharmacogenetic testing etc.). The geriatric work-up is
aimed at evaluating whether current medications are in-
dicated, whether the relevant conditions are satisfactorily
compensated, whether the dosages are appropriate,
whether the patient has symptoms of ADRs, and
whether drug-drug interactions or drug-disease interac-
tions are present or likely to occur. A drug interaction
database [28], lists of anticholinergic drugs [29, 30], the
STOPP/START criteria [31] and the NORGEP criteria
[32] are also used. The geriatrician is provided with clin-
ical supervision from a senior consultant in geriatric
medicine (TBW).
Meeting between the geriatrician and GP
The main purpose of this meeting is to combine the
competence and knowledge of the geriatrician with that
of the GP. The geriatrician summarises the findings
from the geriatric assessment and medication review,
and the two physicians discuss the patient’s drug list sys-
tematically. The geriatrician may suggest changes in the
drug regimen, but the GP retains the medical responsi-
bility for the patient, and is in charge of all ordinations
and medication changes.
Clinical follow-up
Depending on medication changes that have been done,
the two physicians arrange the necessary follow-up within
the project period. The follow-up can consist of a clinical
evaluation, further drug adjustments, blood tests etc., and
can be carried out by the GP, the geriatrician or through
telephone contact with the patient, the relative or the
home nursing service, depending on the circumstances.
Control group
The control group receives “usual care” from their GPs
during the study period, but the GPs in the control
group are offered our assistance in performing medica-
tion reviews after the study period is completed.
Outcome measures
Follow-up occurs at 16 and 24 weeks (±2 weeks) after
baseline registrations, in order to study the course of
any change over time.
Primary outcome measure
The primary endpoint is change in health-related quality
of life (HRQoL), measured by the 15D instrument
(single index version) at 16 weeks. 15D is a generic, 15-
dimensional instrument concerning different aspects of
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HRQoL [33, 34] that has been used in similar geriatric in-
terventions [35, 36]. The dimensions are mobility, vision,
hearing, breathing, sleeping, eating, speech, elimination,
usual activities, mental function, discomfort and symp-
toms, depression, distress, vitality and sexual activity. Each
dimension is rated on an ordinal scale with five levels, and
the respondent chooses the level best describing his/her
present health status. The 15D can be used both as a pro-
file measure and as a single index. The single index, repre-
senting the overall HRQoL, varies between 0 (poorest
HRQoL) and 1 (excellent HRQoL), and is calculated by
using a set of population-based preference or utility
weights [33, 37]. Usually, the 15D questionnaire is filled in
by the individual whom it concerns, but it is also validated
for proxy raters.
We hypothesise that most improvements in the total
drug regimen of frail older patients, such as better pain
control, better symptom control in heart failure, less par-
kinsonian side effects, less iatrogenic dehydration or less
sedation, have the potential to improve HRQoL. Accord-
ingly, in our opinion 15D is an appropriate outcome
measure when the aim is to improve the total drug regi-
men in an individualised manner across a broad
spectrum of drug classes within a heterogeneous group
of older users of multiple drugs. The patients included
in our study are old, and many are not familiar with self-
administration of questionnaires of this kind. 15D is
therefore administered by interview. This is done by the
research assistant, blind to group allocation. If the pa-
tient has a moderate or severe dementia (CDR > 1), and/
or the research assistant considers that they do not
understand the questionnaire, the interview is carried
out with the closest proxy. To account for patients who
might lose their ability to respond to 15D during the
follow-up period, and in order to compare the answers
given by patients themselves and their proxies, we ad-
minister 15D to the closest proxy in all cases.
Secondary outcome measures
Secondary endpoints are on the patient, family and local
community level.
1. Patient-related endpoints
– 15D after 24 weeks
– Short Physical Performance Battery (SPPB), a
simple test of mobility that combines the results
of walking speed, chair stand and balance tests [38]
– Gait speed [39]
– Hand grip strength (hand dynamometry)
– Functional Independence Measure (FIM), a
measure of physical and cognitive disability [40]
– Trail Making Test A and B, measuring processing
speed, focused and split attention, and executive
functioning [41]
– “Digit Span”, a digit repetition test of working
memory, measuring attention [42]
– Five Digits Test, measuring attention and
executive functions [43]
– Appropriateness of current prescribing as
assessed by the Medication Appropriateness
Index (MAI) [44] and the Assessment of
Underutilization (AOU) [45]
– Number of falls during the follow-up period
– Orthostatic blood pressure
– Weight
– All changes in the pharmacotherapy taking place
during the intervention and follow-up period
– Mortality
2. Family-related endpoints
– Carer burden according to the Relative Stress
Scale (RSS) [46]
3. Endpoints related to the local community and use of
health services
– Hospital admissions (with reasons)
– Number of days the patient has spent in his or
her own home (in contrast to being in hospital,
nursing home or other institutions)
– Admission to permanent institutional care
– Current use of home nursing service (hours
per week)
Background variables
The outcomes are measured at baseline, in order to check
and adjust for possible inequalities. In addition, the follow-
ing descriptive variables are registered:
– Demographic data
– Diagnoses according to ICD-10
– Cumulative Illness Rating Scale (CIRS) [47]
– Clinical Dementia Rating Scale (CDR) [48]
– Course of cognitive symptoms during the last
10 years, according to the Informant Questionnaire
on Cognitive Decline in the Elderly (IQCODE) [49]
– Nutritional status, assessed by the Mini Nutritional
Assessment Short Form (MNA-SF) [50]
– Current drug use
Data collection
Background information on diagnoses and comorbidity
are obtained from the GP’s electronic patient records.
The patient receives three home visits from the research
assistant; at baseline, 16 and 24 weeks (±2 weeks). These
visits take place where the patient is living at that mo-
ment; this might be the patient’s own home, a nursing
facility or a rehabilitation institution. All assessments
directly involving the patient are performed at these
visits. Proxy information is collected through telephone
calls and/or questionnaires sent by mail, if the proxy is
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not present at the home visit. Updated drug lists are ob-
tained at all assessment points. The MAI [44] and AOU
[45] are assessed by clinical pharmacists and geriatri-
cians not involved in the intervention. The use of home
nursing service and admissions to hospital, nursing
home or other institutions is registered. In case of hos-
pital admissions, the discharge summary is obtained. See
Table 1 for study assessment procedures and timetable.
Sample size, statistical power and statistical analysis
The primary endpoint 15D is on an interval scale, and is
expected to be reasonably normally distributed. We will
analyse this measure by ANCOVA, as recommended by
Vickers and Altman [51]. Other outcome measures will
be analysed by ANCOVA (continuous data) or logistic re-
gression (categorical data) as appropriate. Non-normally
distributed variables will be transformed in order to try to
achieve a distribution that is more feasible for analysis.
Robust estimation of standard errors will be used to han-
dle within-cluster (physician) correlation. A detailed statis-
tical analysis plan will be developed that will detail
imputation processes for missing data etc.
The number of patients in the intervention group is
planned to be approximately 100, and each GP can par-
ticipate with 1–5 patients. This means that the number
of GPs (clusters) will be 20–100 in the intervention
group. A similar number of patients and GPs will be in-
cluded in the control group.
It is difficult to make valid assumptions on the correl-
ation between patients within each cluster. In order to
estimate the power of the study, we have chosen to esti-
mate power in a worst case (perfect correlation) and a
best case (no correlation) scenario. The true correlation
is expected to be much closer to the latter, as the poten-
tial for intervention will vary between the individual
patients. Based on previous studies using 15D, the stand-
ard deviation of change over time is expected to be
between 0.07 and 0.08 [35, 36, 52]. The minimum im-
portant change (MIC) for the change in 15D scores is ±
0.015 [53]. A change of more than 0.035 in the negative
direction represents “much worse HRQoL” and a change
of more than 0.035 in the positive direction “much bet-
ter HRQoL” [53]. Based on previous studies, in addition
to a pilot study, we believe that our intervention is
extensive enough to potentially improve the patients
HRQoL to “much better” (>0.035). As can be seen from
Table 2, the power to detect a difference of 0.035 will be
in the range 59 to 94%, and most probably > 80%.
Discussion
Polypharmacy and inappropriate drug use constitute a
major health risk for elderly patients. On the other side,
comorbid conditions and bothersome symptoms may give
good reasons to prescribe many drugs. The challenge is to
personalise the polypharmacy and to find the best com-
bination of drugs for each individual patient. For this pur-
pose, thorough clinical evaluations and close monitoring
of the patient’s condition is necessary.
When designing the COOP study, we emphasised
examination of real-life scenarios. Our intention is to indi-
vidualise the treatment, but at the same time to evaluate
Table 1 Study assessment procedures and timetable
Baseline
visit
16 weeks
follow-up
24 weeks
follow-up
Assessments directly involving
the patient
Demographics, diagnoses, CIRS,
MNA-SF
x
15D x x x
SPPB + gait speed x x x
Hand grip strength x x x
Trail Making Test A + B x x x
Five Digits Test x x x
Digit Span x x x
Falls x x
Orthostatic blood pressure x x x
Weight x x x
Assessments of drug use
Current drug use and changes in
pharmacotherapy
x x x
MAI x x x
AOU x x x
Assessments based on observation
and/or proxy information
FIM x x x
CDR x
Assessments based on information
from a close relative
15D x x x
RSS x x x
IQCODE x
Administrative data
Hospital admissions
(with reasons)
x x
Number of days in own home x x
Admission to permanent institutional
care
x x
Use of home nursing service
(hours per week)
x x x
Mortality x x
Abbreviations: CIRS Cumulative Illness Rating Scale, MNA-SF Mini Nutritional
Assessment Short Form, SPPB Short Physical Performance Battery, MAI
Medication Appropriateness Index, AOU Assessment of Underutilization, FIM
Functional Independence Measure, CDR Clinical Dementia Rating Scale, RSS
Relative Stress Scale, IQCODE Informant Questionnaire on Cognitive Decline in
the Elderly
Romskaug et al. Trials  (2017) 18:158 Page 6 of 9
the intervention with stringent scientific methods. In our
opinion, the project is innovative in improving cooper-
ation between hospital specialists and the primary health
care system and evaluating the effect with patient-related
outcome measures.
A majority of previous interventions for improving
drug treatment among older adults have been evaluated
by the use of surrogate outcomes, such as the number of
prescribed drugs [23] or prevalence of PIMs [54], but this
does not necessarily indicate whether the patient has really
benefited from the intervention. We have chosen patient-
relevant outcome measures, and will hopefully be able to
contribute with valuable knowledge about clinical effects
of comprehensive medication reviews.
There are some limitations to the study. The partici-
pants will be old and multimorbid, and prone to experi-
ence new illnesses and clinical deterioration during the
study period, regardless of the intervention. This might
make the intervention less powerful. It is also possible that
the GPs who choose to participate are particularly inter-
ested in drug treatment in the elderly, and therefore have
more knowledge and awareness about this topic than GPs
that do not participate. The participating patients might
therefore be better followed up beforehand, making it less
likely that the intervention will give any effects.
The patients and their relatives are not blinded. There
is a risk that the research assistant might be unblinded,
even if it is clearly explained to the participants that they
should not reveal their group allocation. Nor are the
GPs blinded, and the GPs in the control group may pay
extra attention to the drug treatment for their patients
during the study period, even if they are not provided
with advice from the geriatrician.
Since our aim is to address the various comorbidities
and clinical problems that are unique for each participat-
ing patient, the intervention is not completely standar-
dised. Successful interventions for geriatric patients have
often been of a complex type [55–57], whereas the im-
plementation of one single measure will be less likely to
give an effect. A major challenge when studying complex
interventions is to describe the intervention with suffi-
cient precision as to facilitate replication [57]. Our main
strategy for this will be to compensate for the necessary
degree of pragmatism in the interventional approach
with a detailed description of the interventions that were
in fact carried out, in particular changes in the drug reg-
imens of the individual patients.
This is quite an extensive intervention, but if it is effect-
ive, we will argue that it can be carried out for those pa-
tients having the most complex polypharmacy – within
the existing framework of a geriatric outpatient clinic.
Trial status
The first patient was included on 17 March 2015. The
study is ongoing.
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